Greenwich LifeSciences is a biopharmaceutical company that develops cancer immunotherapies for HER2/neu-expressing cancers, focusing on breast cancer. They recently completed a clinical trial for their immunotherapy, GP2, which aims to prevent breast cancer recurrences in patients who have undergone surgery. The company was incorporated in 2006 and is headquartered in Stafford, Texas.